Skip to search formSkip to main contentSkip to account menu

fresolimumab

A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential… 
National Institutes of Health

Related topics

Related topics

6 relations
Antibody-Dependent Cellular CytotoxicityT-Cell ActivationTransforming Growth Factor betaantigen binding

Narrower (1)

GC1008

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
BackgroundWe previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast… 
Review
2018
Review
2018
Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment
Osteosarcomas are the most frequent form of primary bone tumors and mainly affect children, adolescents, and young adults… 
Highly Cited
2018
Highly Cited
2018
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Purpose: This study examined the feasibility, efficacy (abscopal effect), and immune effects of TGFβ blockade during radiotherapy… 
Review
2016
Review
2016
Targeted Therapy in Systemic Sclerosis
Targeted therapies use an understanding of the pathophysiology of a disease in an individual patient. Although targeted therapy… 
Highly Cited
2015
Highly Cited
2015
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
Transforming growth factor–β (TGF-β) signaling is involved in glioma development. The monoclonal antibody fresolimumab (GC1008… 
2014
2014
Anti-transforming growth factor-β therapy in patients with myelofibrosis
Bone marrow fi brosis (BMF), in the myeloproliferative neoplasm (MPN) myelofi brosis (MF), is the result of a complex and yet not… 
2014
2014
Abstract 633: Inhibition of TGFβ as a strategy to convert the irradiated tumor into in situ individualized vaccine
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Accumulating data support the concept that ionizing… 
Highly Cited
2011
Highly Cited
2011
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis
Primary focal segmental glomerulosclerosis (FSGS) is a disease with poor prognosis and high unmet therapeutic need. Here, we… 
Highly Cited
2011
Highly Cited
2011
PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models
Transforming growth factor-β (TGF-β) promotes cancer invasion and metastasis and is therefore a potential drug target for cancer… 
Review
2011
Review
2011
Antibody targeting of TGF-β in cancer patients.
The role of TGF-β in tumor development and progression is complex. Genetic mutations that disrupt the antiproliferative signaling… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)